100114-19-0

Usage

Uses

Used in Pharmaceutical Industry:
3(2H)-Pyridazinone, 5,6-dimethylis used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic benefits. Its unique structure allows for the creation of molecules with specific biological activities, enhancing the range of treatments available for various health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 3(2H)-Pyridazinone, 5,6-dimethylis utilized as a precursor in the production of agrochemicals, specifically pesticides and herbicides. Its incorporation into these products can lead to the development of more effective and targeted agricultural solutions, contributing to increased crop yields and protection against pests.
Used in Medicinal Chemistry Research:
3(2H)-Pyridazinone, 5,6-dimethylserves as a valuable tool in medicinal chemistry research, where it is employed to explore and understand the structure-activity relationships of potential drug candidates. Its versatility in chemical modifications makes it an ideal candidate for probing the mechanisms of action and optimizing the pharmacological properties of new compounds.
Used in Drug Discovery:
3(2H)-Pyridazinone, 5,6-dimethylis used in drug discovery efforts to identify and develop novel therapeutic agents with anti-inflammatory and analgesic properties. Its potential to modulate biological pathways involved in inflammation and pain makes it a promising candidate for the treatment of various conditions, including chronic pain and inflammatory diseases.

Upstream product

• 101861-29-4 5,6-dimethyl-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 
• 6628-79-1 3-methyllevulinic acid 
• 40380-36-7 5,6-dimethyl-3-oxo-2,3-dihydropyridazine-4-carbonitrile 

Downstream Products

• 873397-60-5 6-Chlor-3,4-dimethyl-pyridazin 

Relevant academic research and scientific papers

Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists

(Table presented.). Formyl peptide receptors (FPRs) are G-protein-coupled receptors that play an important role in the regulation of inflammatory process and cellular dysfunction. In humans, three different isoforms are expressed (FPR1, FPR2, and FPR3). FPR2 appears to be directly involved in the resolution of inflammation, an active process carried out by specific pro-resolving mediators that modulate specific receptors. Previously, we identified 2-arylacetamido pyridazin-3(2H)-ones as FPR1- or FPR2-selective agonists, as well as a large number of mixed-agonists for the three isoforms. Here, we report a new series of 2-arylacetamido pyridazinones substituted at position 5 and their development as FPR agonists. We also synthesized a new series of 2-oxothiazolones bearing a 4-bromophenylacetamido fragment, which was fundamental for activity in the pyridazinone series. The compounds of most interest were 4a, a potent, mixed FPR agonist recognized by all three isotypes (FPR1 EC50 = 19 nM, FPR2 EC50 = 43 nM, FPR3 EC50 = 40 nM), and 4b, which had potent activity and a preference for FPR2 (EC50 = 13 nM). These novel compounds may represent valuable tools for studying FPR activation and signaling. Drug Dev Res 78 : 49–62, 2017.

Endothelin receptor antagonists

This invention relates to pyridizinone derivatives of formula I STR1 wherein the various substituents are defined in the specification, and salts thereof, which have useful pharmacological properties, in particular endothelin receptor-antagonistic properties. The compounds are thus useful for the treatment of illnesses associated with endothelin activities, such as hypertension, cardiac insufficiency, coronary heart disease, renal, cerebral and myocardial ischaemia, renal insufficiency, cerebral infarct, subarachnoid haemorrhage, arteriosclerosis pulmonary high blood pressure, inflammations, asthma, prostate hyperplasia, endotoxic shock and in complications after the administration of immunosuppressants which produce renal vasoconstriction.